Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) — Stella

Recruiting

Back to Orbitopathy, Graves trials

Trial locations(1 site)

Poland

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw

Key details

Sponsor

Medical University of Warsaw

Enrollment target

~30 participants

Started

May 2021

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 80 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov